Discussion

Human African trypanosomiasis is a fatal infection, prevalent in sub-Saharan Africa. There is a need for new drugs to treat this disease, to support treatment and an eradication agenda. In the Drug Discovery Unit, we have run a programme to identify potential drug candidates for this disease. These have been run as both target-based programmes and phenotypic programmes. In this presentation, I will summarise some of our experiences and discuss the advantages and disadvantages of both approaches.